ELOX

NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

Data from Eloxx's proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subjects in Phase 1 trial of ZKN-013 WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases w

4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for additional $3.2 million financing to advance our clinical programs WATERTOWN, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (OTC:ELOX), a leader in ribosomal RNA-targeted gene

NT 10-Q - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome Pre-Investigational New Drug (IND) Meeting Requested with U.S. FDA for ELX-02 to Discuss Planned next Study In Nonsense Mutation Alport Syndrome Signed Global Licensing Partnership for ZKN-013 with Almirall Pharmaceuticals with $3M upfront and up to $470M in milestones and Tiered Royalties on Global Sales New Paper Published on Autosomal Dominant Polycystic Kidney Disease (ADPKD) shows that ELX-02 treatment prevents cyst formation in diseased PKD organoids with nonsense mutations and a single healthy gene copy WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWI

NT 10-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutationsZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC:ELOX) announced today that the companies have entered into an exclusive license agr

Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with nonsense mutations ZKN-013 is a phase I ready oral therapy designed to overcome nonsense mutations that cause a premature stop codon resulting in nonfunctional protein production for example in recessive Dystrophic Epidermolysis Bullosa (RDEB), Junctional Epidermolysis Bullosa (JEB) and familial adenomatous polyposis (FAP) Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC:ELOX) announced today that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains

4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

4 - Eloxx Pharmaceuticals, Inc. (0001035354) (Issuer)

S-3 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

S-8 - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)

8-K - Eloxx Pharmaceuticals, Inc. (0001035354) (Filer)